DK2207529T3 - Lægemiddelkerner til langvarig frigivelse af terapeutiske midler - Google Patents

Lægemiddelkerner til langvarig frigivelse af terapeutiske midler Download PDF

Info

Publication number
DK2207529T3
DK2207529T3 DK08830451T DK08830451T DK2207529T3 DK 2207529 T3 DK2207529 T3 DK 2207529T3 DK 08830451 T DK08830451 T DK 08830451T DK 08830451 T DK08830451 T DK 08830451T DK 2207529 T3 DK2207529 T3 DK 2207529T3
Authority
DK
Denmark
Prior art keywords
drug
core
therapeutic agent
drug core
agent
Prior art date
Application number
DK08830451T
Other languages
English (en)
Inventor
Deepank Utkhede
Robert W Shimizu
Rachna Jain
Stephen Boyd
Hanson S Gifford
Juan Jr Eugene De
Cary J Reich
Original Assignee
Mati Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mati Therapeutics Inc filed Critical Mati Therapeutics Inc
Application granted granted Critical
Publication of DK2207529T3 publication Critical patent/DK2207529T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/2036—Silicones; Polysiloxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2230/0063—Three-dimensional shapes
    • A61F2230/0069—Three-dimensional shapes cylindrical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/00772—Apparatus for restoration of tear ducts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
    • A61L2300/802—Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Plastic & Reconstructive Surgery (AREA)
  • Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)

Claims (18)

  1. so
    1. Lægemiddelindsats, der er tilpasset til placering i et tårekanalsimplantat, hvilket tårekanalsimplantat er tilpasset til indsætning via et tårepunkt i øjet for at befinde sig i øjets canaliculus, hvilken indsats omfatter en lægemiddelkeme og et hylsterlegeme, der delvist dækker lægemiddelkemen, hvilken lægemiddelkeme omfatter et terapeutisk middel og en matrix, hvilket terapeutisk middel er udvalgt fra gruppen bestående af bimatoprost, latanoprost og travoprost, hvilken matrix omfatter en siliconepolymer, hvilket hylsterlegeme er placeret over en del af lægemiddelkemen for at hæmme frigivelse af midlet fra delen og for således at definere mindst én eksponeret overflade af lægemiddelkemen, der er tilpasset til at frigive midlet til øjet eller det omgivende væv eller begge efter kontakt med tårevæske, når implantatet er indsat i en patient, og hvor en mængde af det terapeutiske middel i en makroskopisk volumetrisk del af lægemiddelkemen maksimalt varierer med 30 % fra en mængde af det terapeutiske middel i en hvilken som helst anden tilsvarende makroskopisk volumetrisk del af lægemiddelkemen.
  2. 2. Lægemiddelindsats ifølge krav 1, hvor: a) det terapeutiske middel ensartet og homogent dispergeres gennem matrixen; eller b) det terapeutiske middel mindst delvist danner faste eller flydende inklusioner inde i matrixen.
  3. 3. Lægemiddelindsats ifølge krav 1 eller 2, hvor mængden af det terapeutiske middel i den makroskopiske vo lumetriske del af lægemiddelkemen maksimalt varierer med 10 % fra mængden af det terapeutiske middel i en hvilken som helst anden tilsvarende makroskopisk volumetrisk del af lægemiddelkemen.
  4. 4. Flerhed af lægemiddelindsatseme ifølge et hvilket som helst af kravene 1 -3, hvor hver af flerheden af indsatserne omfatter en koncentration af midlet, der maksimalt varierer med 30 % fra koncentrationer af midlerne i andre indsatser af flerheden.
  5. 5. Flerhed af lægemiddelindsatser ifølge krav 4, hvor koncentrationen af midlet maksimalt varierer med 10 % derimellem.
  6. 6. Lægemiddelindsats ifølge et hvilket som helst af kravene 1-5, hvor lægemiddelkemen omfatter 0,1 vægt-% til 50 vægt-% af midlet.
  7. 7. Lægemiddelindsats ifølge et hvilket som helst af kravene 1-6, hvor hylsterlegemet omfatter en polymer, der omfatter mindst ét af polyimid, PMMA eller PET, hvor polymeren er ekstruderet eller støbt; eller et metal indeholdende rustfrit stål eller titan.
  8. 8. Lægemiddelindsats ifølge et hvilket som helst af kravene 1 -7, hvor lægemiddelindsatsen omfatter et materiale til ændring af frigivelseshastigheden omfattende et inert fyldstof, et salt, et overfladeaktivt middel, et dispergeringsmiddel, en anden polymer, en oligomer eller en kombination deraf.
  9. 9. Lægemiddelindsats ifølge et hvilket som helst af kravene 1-8, hvor lægemiddelkemen i alt væsentligt er cylindrisk i form, har en akse, hvor den eksponerede overflade af lægemiddelkemen placeres på en ende af den cylindriske form, og en overflade af lægemiddelkemen, der er dækket af hylsterlegemet, udgør en rest af overfladen af den cylindriske form.
  10. 10. Lægemiddelindsats ifølge et hvilket som helst af kravene 1-9, hvor midlet er opløst i matrixen i lægemiddelkemen.
  11. 11. Lægemiddelindsats ifølge et hvilket som helst af kravene 1-10, hvor midlet er latanoprost.
  12. 12. Lægemiddelindsats ifølge et hvilket som helst af kravene 1-10, hvor midlet er bimatoprost.
  13. 13. Lægemiddelindsats ifølge et hvilket som helst af kravene 1-12, hvor kernen omfatter to eller flere terapeutiske midler.
  14. 14. Lægemiddelindsats ifølge krav 13, hvor lægemiddelindsatsen omfatter to lægemiddelkemer, der er placeret i hylsterlegemet, hvor en første lægemiddelkeme omfatter et første middel og en første matrix, og en anden lægemiddelkeme omfatter et andet middel og en anden matrix, hvor det første middel og det andet middel er forskellige, og hvor den første matrix og den anden matrix enten er ens eller adskiller sig fra hinanden; hvor implantatet omfatter en åbning, der er tilpasset til at modtage den første og den anden kerne, der er placeret i hylsterlegemet, hvilke lægemiddelkemer er tilpasset til at blive placeret i hylsteret i åbningen af implantatet.
  15. 15. Lægemiddelindsats ifølge krav 14 hvor det første terapeutiske middel har en ffigørelsesprofil, hvor det første middel frigives ved terapeutiske niveauer over et første tidsrum og det andet terapeutiske middel har en anden frigørelsesprofil, hvor det andet middel frigøres ved terapeutiske niveauer over det andet tidsrum.
  16. 16. Fremgangsmåde til fremstilling af en lægemiddelindsats, der er tilpasset til anbringelse i et tårekanalsimplantat ifølge et hvilket som helst af kravene 1 til 15, hvilken fremgangsmåde omfatter injektion ind i hylsterlegemet, ved en temperatur på mindre end 25 °C, af en blanding omfattende en matrixprækursor og det terapeutiske middel, således at hylsterlegemet i alt væsentligt fyldes dermed; derefter hærdning af blandingen i hylsterlegemet for i hylsterlegemet at danne lægemiddelkemen.
  17. 17. Terapeutisk middel, hvilket terapeutisk middel er udvalgt fra gruppen bestående af bimatoprost, latanoprost, og travoprost, til anvendelse ved behandling af en lidelse hos en patient, hvilket terapeutisk middel er omfattet af lægemiddelindsatsen ifølge et hvilket som helst af kravene 1-15, hvor det terapeutiske middel er tilpasset til at behandle lidelsen, hvor lidelsen omfatter glaukom, og hvor implantatet skal indsættes i patienten, i eller i umiddelbar nærhed af ét af patientens øjne, således at det terapeutiske middel frigøres i kropsvæv eller -fluid. ao
  18. 18. Anvendelse af en lægemiddelindsats ifølge et hvilket som helst af kravene 1-15 i fremstillingen af et implantat til tårekanalen, hvilket implantat er tilpasset til behandling af en lidelse hos en patient, der har behov derfor.
DK08830451T 2007-09-07 2008-09-05 Lægemiddelkerner til langvarig frigivelse af terapeutiske midler DK2207529T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US97082007P 2007-09-07 2007-09-07
US97070907P 2007-09-07 2007-09-07
US97069907P 2007-09-07 2007-09-07
US4931708P 2008-04-30 2008-04-30
PCT/US2008/010487 WO2009035562A2 (en) 2007-09-07 2008-09-05 Drug cores for sustained release of therapeutic agents

Publications (1)

Publication Number Publication Date
DK2207529T3 true DK2207529T3 (da) 2015-03-09

Family

ID=39874137

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08830451T DK2207529T3 (da) 2007-09-07 2008-09-05 Lægemiddelkerner til langvarig frigivelse af terapeutiske midler
DK12192860.0T DK2614844T3 (da) 2007-09-07 2008-09-05 Fremgangsmåde til fremstilling af lægemiddelindlæg til langvarig frigivelse af terapeutiske midler

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK12192860.0T DK2614844T3 (da) 2007-09-07 2008-09-05 Fremgangsmåde til fremstilling af lægemiddelindlæg til langvarig frigivelse af terapeutiske midler

Country Status (18)

Country Link
US (5) US20090104243A1 (da)
EP (2) EP2207529B1 (da)
JP (5) JP5555162B2 (da)
KR (3) KR101571434B1 (da)
CN (2) CN103349799B (da)
AU (1) AU2008300013A1 (da)
BR (1) BRPI0817075A2 (da)
CA (1) CA2698573C (da)
DK (2) DK2207529T3 (da)
ES (2) ES2538838T3 (da)
IL (2) IL253005A0 (da)
MX (1) MX2010002616A (da)
NZ (2) NZ598483A (da)
RU (1) RU2478366C2 (da)
SG (1) SG184738A1 (da)
TW (1) TWI543776B (da)
WO (1) WO2009035562A2 (da)
ZA (1) ZA201001586B (da)

Families Citing this family (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US7291125B2 (en) 2003-11-14 2007-11-06 Transcend Medical, Inc. Ocular pressure regulation
US20050232972A1 (en) * 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
US7922702B2 (en) 2004-07-02 2011-04-12 Qlt Inc. Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device
BRPI0612350B8 (pt) 2005-05-04 2021-06-22 Etech Ag elemento de união e material protético
SG170816A1 (en) 2006-03-31 2011-05-30 Qlt Plug Delivery Inc Drug delivery methods, structures, and compositions for nasolacrimal system
CA2667890C (en) * 2006-10-31 2015-01-27 Surmodics Pharmaceuticals, Inc. Spheronized polymer particles
EP2865361B1 (en) 2007-09-07 2019-05-22 Mati Therapeutics Inc. Lacrimal implants and related methods
US9011361B2 (en) 2007-09-07 2015-04-21 Mati Therapeutics Inc. Lacrimal implant detection
DK2207529T3 (da) 2007-09-07 2015-03-09 Mati Therapeutics Inc Lægemiddelkerner til langvarig frigivelse af terapeutiske midler
TW200930343A (en) 2007-09-21 2009-07-16 Organon Nv Drug delivery system
KR20100136453A (ko) * 2008-02-18 2010-12-28 큐엘티 플러그 딜리버리, 인코포레이티드 누관 임플란트 및 이와 관련된 방법
CN104623741A (zh) 2008-04-30 2015-05-20 马缇医疗股份有限公司 复合泪管植入物及相关方法
CA2722971C (en) * 2008-05-09 2019-05-07 Qlt Plug Delivery, Inc. Sustained release delivery of active agents to treat glaucoma and ocular hypertension
JP2011522720A (ja) 2008-05-30 2011-08-04 キューエルティー プラグ デリバリー，インク． 表面処理された埋め込み可能アーティクルおよび関連方法
DE102008002396A1 (de) * 2008-06-12 2009-12-17 Biotronik Vi Patent Ag Implantierbares Wirkstoffreservoir und Vorrichtung mit einem implantierbaren Wirkstoffreservoir
GB2460915B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
EP2303184A4 (en) * 2008-06-24 2013-06-19 Quadra Logic Tech Inc COMBINATION TREATMENT OF GREEN STAR
CA2730101A1 (en) * 2008-07-08 2010-01-14 Qlt Plug Delivery, Inc. Lacrimal implant body including comforting agent
JP2012512725A (ja) * 2008-12-19 2012-06-07 キュー エル ティー インク． 物質送達用涙点インプラントおよび物質送達方法
WO2010083129A2 (en) * 2009-01-13 2010-07-22 The Regents Of The University Of California Implantable delivery vehicle for ocular delivery of muscarinic antagonists
EP2389221B1 (en) 2009-01-23 2023-08-16 Mati Therapeutics Inc. Sustained released delivery of one or more agents
EP3735947B1 (en) 2009-01-28 2022-05-04 Alcon Inc. Ocular implant delivery system
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
AU2010208046B2 (en) 2009-01-29 2014-10-02 Forsight Vision4, Inc. Posterior segment drug delivery
CN102361603A (zh) * 2009-02-23 2012-02-22 Qlt股份有限公司 泪腺植入物和相关方法
TWI495459B (zh) * 2009-03-31 2015-08-11 Johnson & Johnson Vision Care 淚管塞（二）
US9421127B2 (en) 2009-03-31 2016-08-23 Johnson & Johnson Vision Care, Inc. Punctal plugs
EP2432420A4 (en) * 2009-05-18 2018-01-10 Dose Medical Corporation Drug eluting ocular implant
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
EP2437684B1 (en) 2009-06-03 2022-06-15 ForSight Vision5, Inc. Anterior segment drug delivery
US8808257B2 (en) * 2009-08-31 2014-08-19 Johnson & Johnson Vision Care, Inc. Methods and apparatus for pulsatile release of medicaments from a punctal plug
US20120245539A1 (en) 2009-11-27 2012-09-27 Qlt Inc. Lacrimal implants including split and insertable drug core
WO2011079123A1 (en) * 2009-12-23 2011-06-30 Alimera Sciences, Inc. Method of reducing incidence of intraocular pressure associated with intraocular use of corticosteroids
JP5723531B2 (ja) * 2010-01-20 2015-05-27 Ｄｓファーマアニマルヘルス株式会社 チューブ内に保持された凍結乾燥製剤
US10911515B2 (en) 2012-05-24 2021-02-02 Deka Products Limited Partnership System, method, and apparatus for electronic patient care
US11244745B2 (en) 2010-01-22 2022-02-08 Deka Products Limited Partnership Computer-implemented method, system, and apparatus for electronic patient care
US10453157B2 (en) 2010-01-22 2019-10-22 Deka Products Limited Partnership System, method, and apparatus for electronic patient care
WO2013022801A1 (en) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
US9259352B2 (en) 2010-03-29 2016-02-16 Johnson & Johnson Vision Care, Inc. Punctal plugs
US9259351B2 (en) 2010-03-29 2016-02-16 Johnson & Johnson Vision Care, Inc. Punctal plugs
CA2795706A1 (en) * 2010-04-06 2011-10-13 Allergan, Inc. Sustained-release reservoir implants for intracameral drug delivery
US11033624B2 (en) 2010-06-02 2021-06-15 Novaflux Inc. Medical item for prevention and treatment of ear infection
US20110301555A1 (en) * 2010-06-03 2011-12-08 Gonzalez-Zugasti Javier P Porous matrix drug core for lacrimal insert device
CN107913244A (zh) * 2010-06-30 2018-04-17 赢创德固赛有限公司 具有内芯凸起部的芯鞘型植入装置
WO2012003210A1 (en) * 2010-06-30 2012-01-05 Surmodics Pharmaceuticals, Inc. Implant processing methods for thermally labile and other bioactive agents and implants prepared from same
EP3861969A1 (en) 2010-08-05 2021-08-11 ForSight Vision4, Inc. Injector apparatus for drug delivery
CN103209664A (zh) 2010-08-05 2013-07-17 弗赛特影像4股份有限公司 可植入的治疗装置
AU2011285548B2 (en) 2010-08-05 2014-02-06 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
US8591484B2 (en) 2010-09-15 2013-11-26 AlphaMed, Inc. Lacrimal punctum measurement and occlusion
US9022967B2 (en) 2010-10-08 2015-05-05 Sinopsys Surgical, Inc. Implant device, tool, and methods relating to treatment of paranasal sinuses
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
EP2654715B1 (en) 2010-11-24 2017-01-25 Dose Medical Corporation Drug eluting ocular implant
US20120157938A1 (en) * 2010-12-16 2012-06-21 Tokarski Jason M Punctal plug with drug core retention features
US20120276186A1 (en) * 2011-04-29 2012-11-01 Ghebremeskel Alazar N Sustained release latanoprost implant
US20120312840A1 (en) * 2011-05-13 2012-12-13 Ayako Hasegawa Container closure system with integral antimicrobial additives
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
US10398592B2 (en) 2011-06-28 2019-09-03 Forsight Vision4, Inc. Diagnostic methods and apparatus
WO2013011511A1 (en) * 2011-07-18 2013-01-24 Mor Research Applications Ltd. A device for adjusting the intraocular pressure
US9974685B2 (en) 2011-08-29 2018-05-22 Mati Therapeutics Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
EP3290024B1 (en) 2011-08-29 2019-04-17 Mati Therapeutics Inc. Sustained release delivery of active agents to treat glaucoma and ocular hypertension
JP5989780B2 (ja) 2011-09-14 2016-09-07 フォーサイト・ビジョン５・インコーポレイテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ５，Ｉｎｃ． 眼挿入装置および方法
PT2755600T (pt) 2011-09-16 2021-04-19 Forsight Vision4 Inc Aparelhos de troca de fluidos
US9107737B2 (en) * 2011-11-21 2015-08-18 Alan Schwartz Goggles with facial conforming eyepieces
US8765210B2 (en) 2011-12-08 2014-07-01 Aquesys, Inc. Systems and methods for making gelatin shunts
US9241829B2 (en) * 2011-12-20 2016-01-26 Abbott Medical Optics Inc. Implantable intraocular drug delivery apparatus, system and method
WO2013116061A1 (en) 2012-02-03 2013-08-08 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
TWI556785B (zh) * 2012-03-01 2016-11-11 信迪思有限公司 具軟質芯材之手術用縫合線
US20130245759A1 (en) * 2012-03-09 2013-09-19 The Florida International University Board Of Trustees Medical devices incorporating silicone nanoparticles, and uses thereof
EP3342380B1 (en) 2012-03-26 2024-12-04 Glaukos Corporation System for delivering multiple ocular implants
EP2836170B1 (en) 2012-04-11 2018-02-14 Sinopsys Surgical, Inc. Implantation tools, tool assemblies and kits
US10085633B2 (en) 2012-04-19 2018-10-02 Novartis Ag Direct visualization system for glaucoma treatment
US9241832B2 (en) 2012-04-24 2016-01-26 Transcend Medical, Inc. Delivery system for ocular implant
HK1222810A1 (zh) 2012-05-03 2017-07-14 麦提疗法有限公司 治疗开角型青光眼和高眼压症的药物递送系统和方法
EP2895123B1 (en) * 2012-09-17 2017-06-07 Novartis Ag Expanding ocular implant devices
RU2652063C2 (ru) 2012-10-26 2018-04-24 Форсайт Вижн5, Инк. Офтальмологическая система для замедленного высвобождения лекарственного средства в глазу
CN112932781A (zh) 2013-01-15 2021-06-11 科罗拉多州立大学董事会, 公司实体 泪腺系统给药装置
WO2014116980A1 (en) 2013-01-25 2014-07-31 Sinopsys Surgical, Inc. Paranasal sinus access implant devices and related tools, methods and kits
US10159600B2 (en) 2013-02-19 2018-12-25 Aquesys, Inc. Adjustable intraocular flow regulation
US9125723B2 (en) 2013-02-19 2015-09-08 Aquesys, Inc. Adjustable glaucoma implant
WO2014152959A1 (en) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
EP2978406A1 (en) * 2013-03-27 2016-02-03 Forsight Vision5, Inc. Bimatoprost ocular silicone inserts and methods of use thereof
CN105246438B (zh) 2013-03-28 2018-01-26 弗赛特影像4股份有限公司 用于输送治疗物质的眼科植入物
KR20140144843A (ko) * 2013-06-12 2014-12-22 주식회사 엘지화학 실링부가 경화성 물질로 절연되어 있는 파우치형 전지셀의 제조방법
WO2015027018A1 (en) * 2013-08-21 2015-02-26 Senseonics, Incorporated Drug elution for in vivo protection of bio-sensing analytes
WO2015069433A1 (en) 2013-10-16 2015-05-14 Sinopsys Surgical, Inc. Apparatuses, tools and kits relating to fluid manipulation treatments of paranasal sinuses
RU2648229C1 (ru) 2013-11-14 2018-03-22 Эквисис, Инк. Устройство для введения интраокулярного шунта
WO2015086489A1 (en) 2013-12-11 2015-06-18 Merck Sharp & Dohme B.V. Drug delivery system for delivery of anti-virals
US10413504B2 (en) 2013-12-11 2019-09-17 Merck Sharp & Dohme Corp. Intravaginal ring drug delivery system
WO2015168642A1 (en) * 2014-05-02 2015-11-05 Labib Mohamed E Drug-releasing device usable in mucosal body cavities
AU2015266850B2 (en) * 2014-05-29 2019-12-05 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
ES2803102T3 (es) 2014-07-15 2021-01-22 Forsight Vision4 Inc Dispositivo de administración de implante ocular
WO2016014996A1 (en) 2014-07-24 2016-01-28 Sinopsys Surgical, Inc. Apparatuses, tools, kits and methods relating to paranasal sinus access
RU2017105844A (ru) 2014-08-08 2018-09-11 Форсайт Вижн4, Инк. Стабильные и растворимые составы ингибиторов рецепторных тирозинкиназ и способы их получения
US10912933B2 (en) 2014-08-19 2021-02-09 The Regents Of The University Of California Implants for localized drug delivery and methods of use thereof
US10507101B2 (en) 2014-10-13 2019-12-17 W. L. Gore & Associates, Inc. Valved conduit
CN110478119B (zh) 2014-11-10 2022-04-15 弗赛特影像4股份有限公司 可膨胀药物递送装置和使用方法
CN107645951B (zh) * 2014-11-25 2021-05-04 艾克思摩尔有限公司 用于递送一种或多种生物活性剂的组合物和方法
KR101717585B1 (ko) 2014-12-31 2017-03-20 중앙대학교 산학협력단 약물 방출 조절이 가능한 스캐폴드
US20160296532A1 (en) * 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
US20180193193A1 (en) * 2015-07-06 2018-07-12 The Regents Of The University Of Colorado, A Body Corporate Lacrimal drainage system diagnostic implant
US20180333296A1 (en) * 2015-09-02 2018-11-22 Dose Medical Corporation Drug delivery implants as intraocular drug depots and methods of using same
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) * 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
WO2017087902A1 (en) 2015-11-20 2017-05-26 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
AU2016359288C1 (en) * 2015-11-23 2022-03-17 The Regents Of The University Of Colorado, A Body Corporate Lacrimal system for drug delivery
US12011388B2 (en) * 2016-03-01 2024-06-18 The Hilsinger Company Parent, Llc Therapeutic thermal compress with phase-change material
US11998480B2 (en) * 2016-03-01 2024-06-04 The Hilsinger Company Parent, Llc Self-heating compress for moist heat delivery
US12156831B2 (en) * 2016-03-01 2024-12-03 The Hilsinger Company Parent, Llc Therapeutic eye compress system
WO2017151480A1 (en) * 2016-03-01 2017-09-08 Bruder Healthcare Company, Llc Therapeutic eye mask system
US12029681B2 (en) 2016-03-01 2024-07-09 The Hilsinger Company Parent, Llc Therapeutic eye mask system
CN113017981B (zh) 2016-04-05 2023-07-25 弗赛特影像4股份有限公司 药物递送装置
AU2017252294B2 (en) * 2016-04-20 2021-12-02 Glaukos Corporation Bioresorbable ocular drug delivery device
WO2017201255A1 (en) 2016-05-20 2017-11-23 The Regents Of The University Of Colorado, A Body Corporate Lacrimal drug delivery device
USD871598S1 (en) 2016-11-30 2019-12-31 Bruder Healthcare Company, Llc Therapeutic eye mask
USD844795S1 (en) 2016-11-30 2019-04-02 Bruder Healthcare Company, Llc Therapeutic eye mask
CN108339147B (zh) * 2017-01-24 2021-05-07 沈阳何氏眼产业集团有限公司 玻璃体或视网膜手术切口用粘合剂及粘合系统
US11351058B2 (en) 2017-03-17 2022-06-07 W. L. Gore & Associates, Inc. Glaucoma treatment systems and methods
CA3058097C (en) 2017-04-21 2024-01-02 Novaliq Gmbh Iodine compositions
US12076223B2 (en) * 2017-08-15 2024-09-03 Covidien Lp Methods and tools for treating diseased tissue
JP7408542B2 (ja) 2017-09-20 2024-01-05 シノプシス サージカル インコーポレイテッド 副鼻腔流体アクセス埋め込み器具、アセンブリ、キット、および方法
WO2019070385A2 (en) 2017-10-06 2019-04-11 Glaukos Corporation SYSTEMS AND METHODS FOR PLACING MULTIPLE OCULAR IMPLANTS
CN111655206B (zh) 2017-11-21 2022-10-14 弗赛特影像4股份有限公司 用于可扩展端口递送系统的流体交换装置及使用方法
JP2021530253A (ja) * 2018-03-29 2021-11-11 マティ セラピューティクス，インク． 眼科用徐放性製剤およびドライアイ症候群治療のための使用
KR20260007295A (ko) 2018-05-24 2026-01-13 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
MX2020012459A (es) 2018-05-24 2021-04-28 Celanese Eva Performance Polymers Llc Dispositivo implantable para liberacion sostenida de un compuesto de farmaco macromolecular.
EP3803866A4 (en) 2018-05-24 2022-03-16 Nureva Inc. METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS
CN112566622A (zh) * 2018-06-19 2021-03-26 细胞疗法有限责任公司 用于治疗青光眼或高眼压症的包含眼内压降低剂、cnp化合物、npr-b化合物、tie-2激动剂或神经营养剂的缓释药物递送系统
MX2020014160A (es) * 2018-06-25 2021-03-09 Titan Pharmaceuticals Inc Implantes para liberacion de sustancias farmaceuticas lipofilicas o anfifilicas.
WO2020047221A1 (en) 2018-08-29 2020-03-05 W. L. Gore & Associates, Inc. Drug therapy delivery systems and methods
WO2020047622A1 (en) * 2018-09-05 2020-03-12 Dos Santos Neto Edson USE OF MIOTIC CHOLINERGIC SUBSTANCES AND F2α PROSTAGLANDIN ANALOGUES FOR PREVENTION AND TREATMENT OF MYOPIA
CA3111870C (en) * 2018-09-27 2022-04-12 Novaliq Gmbh Topical sunscreen formulation
EP3856124A1 (en) 2018-09-27 2021-08-04 Novaliq GmbH Lipid barrier repair
US11678983B2 (en) 2018-12-12 2023-06-20 W. L. Gore & Associates, Inc. Implantable component with socket
IT201900003597A1 (it) * 2019-03-12 2020-09-12 Milano Politecnico Dispositivo per il rilascio controllato
US12403291B2 (en) * 2019-08-30 2025-09-02 Intersect Ent, Inc. Submucosal bioresorbable drug eluting platform
US11207267B2 (en) 2019-10-02 2021-12-28 Segal Innovations LLC Bio-adhesive dissolving compounds and device
US12447045B2 (en) 2019-10-02 2025-10-21 Segal Innovations LLC Bio-adhesive dissolving compounds and device
JP6925464B1 (ja) * 2020-02-21 2021-08-25 巨晰光纖股▲ふん▼有限公司 生体活性ガラス薬物キャリア機能付き分流器
CN115515657A (zh) 2020-03-20 2022-12-23 加利福尼亚大学董事会 用于局部药物递送的可植入药物递送设备
US11344526B2 (en) 2020-03-20 2022-05-31 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11173291B2 (en) 2020-03-20 2021-11-16 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11338119B2 (en) 2020-03-20 2022-05-24 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
JP7821487B2 (ja) * 2020-04-20 2026-02-27 エイブルティーエックス リミテッド 眼科デバイス
EP4142664A4 (en) * 2020-04-27 2024-05-29 Ocular Therapeutix, Inc. METHODS FOR TREATING ALLERGIC CONJUNCTIVITIS
US12263304B1 (en) * 2020-12-15 2025-04-01 Jon E Hilliard Face mask impregnated with medicine
CN112618791A (zh) * 2020-12-25 2021-04-09 福建医科大学附属协和医院 聚醚醚酮三维多孔化并修饰聚多巴胺/庆大霉素用于植入物抗菌、抗炎及促进骨整合
CA3209420A1 (en) 2021-02-24 2022-09-01 Peter Jarrett Intracanalicular depot inserter device
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
US12527691B2 (en) 2021-11-05 2026-01-20 W. L. Gore & Associates, Inc. Fluid drainage devices, systems, and methods
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device

Family Cites Families (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865108A (en) * 1971-05-17 1975-02-11 Ortho Pharma Corp Expandable drug delivery device
US3828777A (en) * 1971-11-08 1974-08-13 Alza Corp Microporous ocular device
US3949750A (en) 1974-10-07 1976-04-13 Freeman Jerre M Punctum plug and method for treating keratoconjunctivitis sicca (dry eye) and other ophthalmic aliments using same
US4014335A (en) * 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4205128A (en) * 1976-03-31 1980-05-27 Denki Kagaku Kogyo Kabushiki Kaisha Process for producing immobilized enzyme compositions
US4281654A (en) 1980-04-07 1981-08-04 Alza Corporation Drug delivery system for controlled ocular therapy
US4322323A (en) * 1980-12-01 1982-03-30 Alza Corporation Erodible device comprising surfactant for modifying the rate of erosion of the device
US5053030A (en) 1984-11-07 1991-10-01 Herrick Robert S Intracanalicular implant for horizontal canalicular blockade treatment of the eye
US5049142A (en) * 1984-11-07 1991-09-17 Herrick Robert S Intracanalicular implant for horizontal canalicular blockade treatment of the eye
US4660546A (en) * 1984-11-07 1987-04-28 Robert S. Herrick Method for treating for deficiency of tears
US5229128A (en) * 1986-06-11 1993-07-20 Haddad Heskel M Drug delivery ophthalmic insert and method of preparing same
DE3775880D1 (da) * 1986-09-18 1992-02-20 London School Of Pharmacy Innovations Ltd., London, Gb
US5322691A (en) * 1986-10-02 1994-06-21 Sohrab Darougar Ocular insert with anchoring protrusions
US4983390A (en) * 1987-04-01 1991-01-08 Lee County Mosquito Control District Terrestrial delivery compositions and methods for controlling insect and habitat-associated pest populations in terrestrial environments
FR2618329B1 (fr) * 1987-07-22 1997-03-28 Dow Corning Sa Procede de fabrication d'un anneau capable d'assurer la liberation d'un agent therapeutique, et anneau fabrique par ce procede
US4886488A (en) 1987-08-06 1989-12-12 White Thomas C Glaucoma drainage the lacrimal system and method
US4915684A (en) * 1988-06-21 1990-04-10 Mackeen Donald L Method and apparatus for modulating the flow of lacrimal fluid through a punctum and associated canaliculus
US5133159A (en) * 1989-01-13 1992-07-28 Nestle S.A. Method for polishing silicone products
US4959048A (en) * 1989-01-17 1990-09-25 Helix Medical, Inc. Lacrimal duct occluder
US5098443A (en) * 1989-03-23 1992-03-24 University Of Miami Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents
US5128058A (en) * 1989-05-31 1992-07-07 Hoya Corporation Contact lens cleaner containing a microcapsular polishing agent
IE910450A1 (en) 1990-02-15 1991-08-28 Bausch & Lomb Soft contact lens processing aid
US5163959A (en) 1990-03-29 1992-11-17 Herrick Robert S Method for treating an eye with a canalicular implant having a collapsible flared section
US5171270A (en) 1990-03-29 1992-12-15 Herrick Robert S Canalicular implant having a collapsible flared section and method
US5041081A (en) * 1990-05-18 1991-08-20 Odrich Ronald B Ocular implant for controlling glaucoma
US5116371A (en) * 1990-07-06 1992-05-26 Christensen James M Prosthesis with improved biocompatibility
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5283063A (en) * 1992-01-31 1994-02-01 Eagle Vision Punctum plug method and apparatus
US5334137A (en) * 1992-02-21 1994-08-02 Eagle Vision, Inc. Lacrimal fluid control device
DE69329407T2 (de) 1992-06-02 2001-05-03 Bard Inc C R Verfahren und Implantatvorrichtung für Langzeitwirkstoffabgabe
US5469867A (en) 1992-09-02 1995-11-28 Landec Corporation Cast-in place thermoplastic channel occluder
US5318513A (en) * 1992-09-24 1994-06-07 Leib Martin L Canalicular balloon fixation stent
US5707643A (en) * 1993-02-26 1998-01-13 Santen Pharmaceutical Co., Ltd. Biodegradable scleral plug
JP3000187B2 (ja) * 1993-02-26 2000-01-17 参天製薬株式会社 生体分解性強膜プラグ
US5417651A (en) * 1993-07-01 1995-05-23 Guena; Nicolas Punctum plug and monocanalicular probe for lacrimal pathology
US5770589A (en) * 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
US5423777A (en) * 1993-10-27 1995-06-13 Tajiri; Akira Punctum plug
US5417744A (en) * 1993-12-29 1995-05-23 Ameron, Inc. Optically clear hydrophobic coating composition
US5426166A (en) * 1994-01-26 1995-06-20 Caschem, Inc. Urethane adhesive compositions
US5466233A (en) 1994-04-25 1995-11-14 Escalon Ophthalmics, Inc. Tack for intraocular drug delivery and method for inserting and removing same
JP3486758B2 (ja) 1994-06-24 2004-01-13 株式会社高研 注入可能な涙小管閉鎖剤
US5605696A (en) * 1995-03-30 1997-02-25 Advanced Cardiovascular Systems, Inc. Drug loaded polymeric material and method of manufacture
US5723005A (en) * 1995-06-07 1998-03-03 Herrick Family Limited Partnership Punctum plug having a collapsible flared section and method
US6149684A (en) 1995-06-07 2000-11-21 Herrick; Robert S. Punctum plug having a thin elongated lip and a distal starting tip and method of using
AU6107696A (en) * 1995-06-07 1996-12-30 Keravision, Inc. Radial intrastromal corneal insert and a method of insertion
US5766243A (en) * 1995-08-21 1998-06-16 Oasis Medical, Inc. Abrasive polished canalicular implant
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5741292A (en) * 1995-10-26 1998-04-21 Eagle Vision Punctum dilating and plug inserting instrument with push-button plug release
US5824073A (en) 1996-03-18 1998-10-20 Peyman; Gholam A. Macular indentor for use in the treatment of subretinal neovascular membranes
US5993407A (en) 1996-10-25 1999-11-30 Moazed; Kambiz Thomas Transnasal lacrimal insert
ATE218085T1 (de) * 1996-11-01 2002-06-15 Alcon Lab Inc Polierverfahren für weiche acrylgegenstände
US6254562B1 (en) * 1997-02-04 2001-07-03 Alain Fouere Meatus plug for lachrymal canal capable of being screwed
US6041785A (en) * 1997-03-27 2000-03-28 Eaglevision, Inc. Punctum plug
US6082362A (en) * 1997-03-27 2000-07-04 Eagle Vision, Inc. Punctum plug
US6027470A (en) * 1998-06-10 2000-02-22 Eagle Vision, Inc. Punctum plug and method for inserting the same into the punctual opening
US6016806A (en) * 1997-03-27 2000-01-25 Eaglevision, Inc Punctum plug
US5961370A (en) 1997-05-08 1999-10-05 Chiron Vision Corporation Intraocular lens tumbling process using coated beads
MY125870A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system flow modulator apparatus and method
JPH1147183A (ja) * 1997-08-05 1999-02-23 Kaneka Medics:Kk 涙点プラグ装置
US6306426B1 (en) * 1997-08-11 2001-10-23 Allergan Sales, Inc. Implant device with a retinoid for improved biocompatibility
US5830171A (en) 1997-08-12 1998-11-03 Odyssey Medical, Inc. Punctal occluder
US6060439A (en) 1997-09-29 2000-05-09 Kyzen Corporation Cleaning compositions and methods for cleaning resin and polymeric materials used in manufacture
US6335335B2 (en) 1997-11-05 2002-01-01 Senju Pharmaceutical Co., Ltd. Prolonged-action eye drop
US6203513B1 (en) * 1997-11-20 2001-03-20 Optonol Ltd. Flow regulating implant, method of manufacture, and delivery device
US6290684B1 (en) * 1998-03-02 2001-09-18 Herrick Family Limited Partnership Punctum plug having a collapsible expanded section and distal tip extending substantially perpendicular thereto and method of inserting same
US6196993B1 (en) * 1998-04-20 2001-03-06 Eyelab Group, Llc Ophthalmic insert and method for sustained release of medication to the eye
US6306114B1 (en) 1998-06-16 2001-10-23 Eagle Vision, Inc. Valved canalicular plug for lacrimal duct occlusion
US6117441A (en) * 1998-07-02 2000-09-12 The Population Council, Inc. Silicone core long term androgen delivery implant
JP2000070296A (ja) 1998-08-27 2000-03-07 M L C:Kk 涙道内挿管器具
US6095901A (en) * 1998-12-09 2000-08-01 Alcon Laboratories, Inc. Polishing method for soft acrylic articles
US20040121014A1 (en) * 1999-03-22 2004-06-24 Control Delivery Systems, Inc. Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6234175B1 (en) * 1999-03-23 2001-05-22 Medennium, Inc. Smart ocular plug design and method of insertion for punctal and intracanalicular implants
US6383192B1 (en) * 1999-04-28 2002-05-07 Mlc Limited Company Apparatus for intubation of lacrimal duct
US6428502B1 (en) * 1999-06-25 2002-08-06 Alcon Manufacturing, Ltd. Punctal cannula
US6706275B1 (en) * 1999-09-08 2004-03-16 Matthew W. Camp Scleral plug system
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6264971B1 (en) * 1999-11-04 2001-07-24 Btg International Limited Ocular insert
US6706034B1 (en) 1999-12-30 2004-03-16 Advanced Cardiovascular Systems, Inc. Process for agent retention in biological tissues
US7217263B2 (en) * 2000-01-03 2007-05-15 The Johns Hopkins University Device and method for manual retinal vein catheterization
US20050119737A1 (en) * 2000-01-12 2005-06-02 Bene Eric A. Ocular implant and methods for making and using same
US20030096831A1 (en) 2000-01-18 2003-05-22 Stone Richard A. Ocular growth and nicotinic antagonists
US6344047B1 (en) * 2000-02-02 2002-02-05 Eagle Vision Instrument for inserting a punctum plug and method for manufacturing the instrument
US7867186B2 (en) * 2002-04-08 2011-01-11 Glaukos Corporation Devices and methods for treatment of ocular disorders
US7708711B2 (en) * 2000-04-14 2010-05-04 Glaukos Corporation Ocular implant with therapeutic agents and methods thereof
US6638239B1 (en) 2000-04-14 2003-10-28 Glaukos Corporation Apparatus and method for treating glaucoma
US20040208910A1 (en) 2000-04-26 2004-10-21 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of adrenergic agents
US6375972B1 (en) * 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US20040175410A1 (en) * 2000-04-26 2004-09-09 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors
US6371122B1 (en) * 2000-06-20 2002-04-16 Robert M. Mandelkorn Gauge/dilator apparatus
US6629533B1 (en) 2000-06-30 2003-10-07 Eagle Vision, Inc. Punctum plug with at least one anchoring arm
US6534693B2 (en) * 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
JP2004517674A (ja) * 2000-12-29 2004-06-17 ボシュ・アンド・ロム・インコーポレイテッド 徐放薬物送達装置
JP2004521882A (ja) 2001-01-03 2004-07-22 ボシュ・アンド・ロム・インコーポレイテッド 組立式透過性プラグを備えた徐放薬剤送達装置
WO2002058667A2 (en) * 2001-01-26 2002-08-01 Bausch & Lomb Incorporated Improved process for the production of sustained release drug delivery devices
US20020193441A1 (en) 2001-02-21 2002-12-19 Robertson Stella M. Prostanoid therapies for the treatment of glaucoma
US6713081B2 (en) * 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
WO2002080811A2 (en) 2001-04-07 2002-10-17 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US6981958B1 (en) 2001-05-02 2006-01-03 Glaukos Corporation Implant with pressure sensor for glaucoma treatment
US6605108B2 (en) * 2001-04-13 2003-08-12 Eagle Vision, Inc. Monocanalicular stent
US6982090B2 (en) * 2001-05-10 2006-01-03 Gillespie Donald E More easily visualized punctum plug configurations
EP1397132A4 (en) 2001-05-25 2006-12-13 Valley Forge Pharmaceuticals I OPHTHALMIC PIRENZEPINE GEL
US7404825B2 (en) 2001-06-11 2008-07-29 Herrick Ii Robert S Implant capable of forming a differential image in an eye
US20050129732A1 (en) * 2001-07-13 2005-06-16 Flow Focusing, Inc. Biodegradable, antibiotic, controlled release tape
FR2829019B3 (fr) 2001-08-31 2003-10-31 Alain Fouere Bouchons lacrymaux et methodes de mise en place de ces dispositifs
NZ530550A (en) * 2001-09-11 2004-11-26 Smart Drug Systems Inc Preparation of sustained release pharmaceutical composition
US8491549B2 (en) * 2001-11-21 2013-07-23 Iscience Interventional Corporation Ophthalmic microsurgical system
US6729939B2 (en) * 2001-12-17 2004-05-04 Bausch & Lomb Incorporated Polishing method for intraocular lens
US7204995B2 (en) * 2002-01-31 2007-04-17 El-Sherif Dalia M Treatment and control of dry eye by use of biodegradable polymer capsules
US20040147870A1 (en) * 2002-04-08 2004-07-29 Burns Thomas W. Glaucoma treatment kit
US9301875B2 (en) 2002-04-08 2016-04-05 Glaukos Corporation Ocular disorder treatment implants with multiple opening
US8871241B2 (en) * 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
US6866563B2 (en) * 2002-06-27 2005-03-15 Bausch & Lomb Incorporated Apparatus and method for target polishing intraocular lenses
FR2841770B1 (fr) 2002-07-05 2004-10-01 Ioltechnologie Production Clou meatique d'obturation d'un meat lacrymal
ES2295647T3 (es) * 2002-07-15 2008-04-16 Alcon, Inc. Composiciones de implante farmaceuticas lipofilas, no polimeras, para uso intraocular.
FR2844182B1 (fr) * 2002-09-11 2004-12-03 Humanoptics Ag Bouchon d'obturation d'un canalicule lacrymal
US7169163B2 (en) * 2002-09-30 2007-01-30 Bruce Becker Transnasal method and catheter for lacrimal system
NZ540885A (en) * 2002-12-20 2009-02-28 Chakshu Res Inc Ophthalmic formulation for the prevention and treatment of ocular conditions
US20040137059A1 (en) * 2003-01-09 2004-07-15 Thierry Nivaggioli Biodegradable ocular implant
DK1592408T3 (da) 2003-01-24 2010-01-04 Psivida Inc Indretning med depotvirkning og fremgangsmåde til okulær indgivelse af adrenergt midler
KR20050108345A (ko) * 2003-01-24 2005-11-16 컨트롤 딜리버리 시스템즈 인코포레이티드 탄산 탈수효소 저해제의 안구 전달을 위한 서방 장치와방법
CA2513443A1 (en) * 2003-02-26 2004-09-10 Medivas, Llc Bioactive stents and methods for use thereof
US6699282B1 (en) 2003-03-06 2004-03-02 Gelsus Research And Consulting, Inc. Method and apparatus for delivery of medication
US20050283109A1 (en) 2003-03-07 2005-12-22 Peyman Gholam A Method and apparatus for lacrimal canal obstruction
CA2524271C (en) * 2003-05-02 2012-09-04 Surmodics, Inc. Controlled release bioactive agent delivery device
US7017580B2 (en) * 2003-05-22 2006-03-28 Clarity Corporation Punctum plug system including a punctum plug and passive insertion tool therefor
US7204253B2 (en) * 2003-05-22 2007-04-17 Clarity Corporation Punctum plug
US20040236343A1 (en) 2003-05-23 2004-11-25 Taylor Jon B. Insertion tool for ocular implant and method for using same
JP4104137B2 (ja) * 2003-05-30 2008-06-18 有限会社エム・エル・シー 涙点プラグ
US7662864B2 (en) 2003-06-04 2010-02-16 Rutgers, The State University Of New Jersey Solution polymerization processes to prepare a polymer that degrades to release a physiologically active agent
JP4339635B2 (ja) 2003-06-12 2009-10-07 有限会社エム・エル・シー 涙点プラグ
US6994684B2 (en) * 2003-06-16 2006-02-07 Alphamed Inc. Punctum plugs having fluid collecting recesses and methods of punctal occlusion
US20040265356A1 (en) 2003-06-30 2004-12-30 Bausch & Lomb Incorporated Drug delivery device
CA2531640C (en) * 2003-07-10 2013-06-18 Galen (Chemicals) Limited Intravaginal drug delivery devices
US7198205B1 (en) * 2003-07-24 2007-04-03 Anderson & Associates, Llc Silicone protective coating
JP4280128B2 (ja) 2003-08-19 2009-06-17 有限会社エム・エル・シー 涙点プラグ
JP2005110765A (ja) 2003-10-03 2005-04-28 M L C:Kk 涙点プラグセット
JP2005110930A (ja) 2003-10-07 2005-04-28 M L C:Kk 涙点プラグセット
US20050129731A1 (en) 2003-11-03 2005-06-16 Roland Horres Biocompatible, biostable coating of medical surfaces
US20050095269A1 (en) * 2003-11-04 2005-05-05 Ainpour Parviz R. Gel plug for blockage of the canaliculus
US20050197614A1 (en) 2004-03-04 2005-09-08 Wilson Pritchard Occlusive biomedical devices, punctum plugs, and methods of use thereof
US20050220882A1 (en) 2004-03-04 2005-10-06 Wilson Pritchard Materials for medical implants and occlusive devices
US20050232972A1 (en) 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
JP2004202276A (ja) 2004-04-16 2004-07-22 M L C:Kk 涙道再建用挿管器具
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
JP2005312835A (ja) 2004-04-30 2005-11-10 M L C:Kk 糸で補強した涙道ステント
US7589057B2 (en) * 2004-04-30 2009-09-15 Allergan, Inc. Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems
JP4644438B2 (ja) 2004-05-11 2011-03-02 有限会社エム・エル・シー ツバつき涙道ステント
JP4510511B2 (ja) 2004-05-18 2010-07-28 有限会社エム・エル・シー ツバを円盤で補強した涙道ステント及び涙道プラグ
US7922702B2 (en) * 2004-07-02 2011-04-12 Qlt Inc. Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device
US7117870B2 (en) * 2004-07-26 2006-10-10 Clarity Corporation Lacrimal insert having reservoir with controlled release of medication and method of manufacturing the same
US20060020253A1 (en) * 2004-07-26 2006-01-26 Prescott Anthony D Implantable device having reservoir with controlled release of medication and method of manufacturing the same
WO2006014793A1 (en) 2004-07-26 2006-02-09 Clarity Corporation Implantable device having reservoir with controlled release of medication and method of manufacturing the same
WO2006031658A2 (en) 2004-09-10 2006-03-23 Allergan, Inc. Therapeutic lacrimal canalicular inserts and related methods
US20060074370A1 (en) * 2004-09-24 2006-04-06 Medennium, Inc. Ocular occluder and method of insertion
MX2007006214A (es) * 2004-11-24 2008-04-16 Therakine Ltd Un implante para suministro de farmaco intraocular.
US20060233858A1 (en) 2005-03-08 2006-10-19 Allergan, Inc. Systems and methods providing targeted intraocular drug delivery
US7862532B2 (en) * 2005-10-07 2011-01-04 Delta Life Sciences, Inc. Punctum plugs having insertion guides and strengthening beams
US20070132125A1 (en) * 2005-12-08 2007-06-14 Bausch & Lomb Incorporated Use of a super-cooled fluid in lens processing
JP4078371B2 (ja) 2006-01-27 2008-04-23 章弘 小栗 涙点プラグ
SG170816A1 (en) 2006-03-31 2011-05-30 Qlt Plug Delivery Inc Drug delivery methods, structures, and compositions for nasolacrimal system
SG138567A1 (en) * 2006-06-21 2008-01-28 Johnson & Johnson Vision Care Punctal plugs for the delivery of active agents
US20080045911A1 (en) 2006-06-21 2008-02-21 Borgia Maureen J Punctal plugs for the delivery of active agents
US9173773B2 (en) 2006-06-21 2015-11-03 Johnson & Johnson Vision Care, Inc. Punctal plugs for the delivery of active agents
US9474645B2 (en) 2006-06-21 2016-10-25 Johnson & Johnson Vision Care, Inc. Punctal plugs for the delivery of active agents
FR2908042B1 (fr) 2006-11-08 2009-06-05 Bruno Fayet Ensemble d'intubation monocanaliculonasal et/ou monocanaliculaire,notamment pour l'imperforation lacrymonasale.
UY30883A1 (es) * 2007-01-31 2008-05-31 Alcon Res Tapones punctales y metodos de liberacion de agentes terapeuticos
WO2009012406A1 (en) 2007-07-17 2009-01-22 Transcend Medical, Inc. Ocular implant with hydrogel expansion capabilities reference to priority document
EP2865361B1 (en) * 2007-09-07 2019-05-22 Mati Therapeutics Inc. Lacrimal implants and related methods
RU2482822C2 (ru) * 2007-09-07 2013-05-27 Клт Инк. Инструменты для вставления и извлечения лакримальных имплантатов
DK2207529T3 (da) 2007-09-07 2015-03-09 Mati Therapeutics Inc Lægemiddelkerner til langvarig frigivelse af terapeutiske midler
CN104623741A (zh) 2008-04-30 2015-05-20 马缇医疗股份有限公司 复合泪管植入物及相关方法
CA2722971C (en) 2008-05-09 2019-05-07 Qlt Plug Delivery, Inc. Sustained release delivery of active agents to treat glaucoma and ocular hypertension

Also Published As

Publication number Publication date
HK1189521A1 (zh) 2014-06-13
KR101571434B1 (ko) 2015-11-24
ZA201001586B (en) 2011-05-25
RU2478366C2 (ru) 2013-04-10
US20140186420A1 (en) 2014-07-03
JP5555162B2 (ja) 2014-07-23
CA2698573C (en) 2017-12-05
HK1155104A1 (en) 2012-05-11
KR20170005905A (ko) 2017-01-16
IL253005A0 (en) 2017-08-31
JP2020062381A (ja) 2020-04-23
CA2698573A1 (en) 2009-03-19
AU2008300013A1 (en) 2009-03-19
JP2010538696A (ja) 2010-12-16
KR20150136140A (ko) 2015-12-04
TW201002367A (en) 2010-01-16
BRPI0817075A2 (pt) 2016-07-26
NZ583678A (en) 2012-03-30
CN103349799A (zh) 2013-10-16
WO2009035562A3 (en) 2009-07-02
JP5933630B2 (ja) 2016-06-15
CN103349799B (zh) 2016-01-20
JP2017205545A (ja) 2017-11-24
NZ598483A (en) 2013-08-30
CN101984745B (zh) 2013-08-14
ES2533359T3 (es) 2015-04-09
JP2016165503A (ja) 2016-09-15
CN101984745A (zh) 2011-03-09
US8628792B2 (en) 2014-01-14
EP2207529A2 (en) 2010-07-21
SG184738A1 (en) 2012-10-30
US20090104243A1 (en) 2009-04-23
EP2614844B1 (en) 2015-04-15
RU2010113387A (ru) 2011-10-20
DK2614844T3 (da) 2015-06-08
US20190105265A1 (en) 2019-04-11
WO2009035562A2 (en) 2009-03-19
US20170304194A1 (en) 2017-10-26
ES2538838T3 (es) 2015-06-24
KR101996336B1 (ko) 2019-07-04
EP2207529B1 (en) 2014-12-31
MX2010002616A (es) 2010-08-04
KR101696301B1 (ko) 2017-01-13
IL273683A (en) 2020-05-31
TWI543776B (zh) 2016-08-01
KR20100063111A (ko) 2010-06-10
JP2014236980A (ja) 2014-12-18
EP2614844A1 (en) 2013-07-17
US20120187594A1 (en) 2012-07-26

Similar Documents

Publication Publication Date Title
DK2207529T3 (da) Lægemiddelkerner til langvarig frigivelse af terapeutiske midler
KR101270113B1 (ko) 비루관계에 대한 약물 전달 방법, 구조, 및 조성물
JP2016127945A (ja) １つまたは複数の薬剤の徐放性送達
HK1155104B (en) Drug cores for sustained release of therapeutic agents
HK1189521B (en) Drug cores for sustained release of therapeutic agents